Search Medical Condition
Please enter condition
Please choose location from dropdown

Tianjin, China, China Clinical Trials

A listing of Tianjin, China, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (66) clinical trials

Prognostic Value of CT dynamIc Myocardial Perfusion in Patients With Obstructive Coronary Artery Stenosis

VALIDITY is a prospective, open-label, multicenter, randomized controlled trial ClinicalTrials.gov number. The study was designed to evaluate the value of noninvasive anatomic CTA combined with functional CTP for the next clinical decision making and the added prognostic value of CTP beyond CTA.

Phase N/A

0.0 miles

Learn More »

Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women

To demonstrate non-inferiority of FE 999049 compared with GONAL-F with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation.

Phase

0.0 miles

Learn More »

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

STUDY BACKGROUND Breast cancer is a serious disease that threatens human health and life. Especially in China, the incidence rate is increasing year by year. According to WHO data, the incidence of breast cancer in China in 2020 will reach 214,000. Selective estrogen receptor modulators (SERMs) are a classic form ...

Phase

0.0 miles

Learn More »

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation

Participants considered an adult according to local regulations at the time of signing informed consent will be randomized in a 1:1 ratio to receive ASP2215 or salvage chemotherapy. Participants will enter the screening period up to 14 days prior to the start of treatment. Prior to randomization, the investigator will ...

Phase

0.0 miles

Learn More »

Compare Chemotherapy of XELOX for 4 Months to 6 Months After D2 Gastrectomy for Gastric Cancer Staged II or III.

Surgical resection is the cornerstone of treatment for patients with localised gastric cancer. Capecitabine plus oxaliplatin for 6 months after D2 gastrectomy is considered as effective postoperative adjuvant treatment for patients with operable stage II or III gastric cancer in CLASSIC trail. However, because of adverse events discontinuations in the ...

Phase

0.0 miles

Learn More »

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP) in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

The purpose of this study is to determine if the addition of daratumumab to VELCADE-melphalan-prednisone (VMP) will improve very good partial response (VGPR) or better compared with VMP alone.

Phase

0.0 miles

Learn More »

A Study to Compare Daratumumab Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

The primary purpose of this study is to compare the efficacy of daratumumab when combined with Velcade (bortezomib) and dexamethasone (DVd) to that of Velcade and dexamethasone (Vd), in terms of progression free survival (PFS) in Chinese participants with relapsed or refractory multiple myeloma (MM).

Phase

0.0 miles

Learn More »

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenstr m's Macroglobulinemia (WM)

Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 3 years), safety follow up (28 days); survival follow-up until data cutoff for final analysis.

Phase

0.0 miles

Learn More »

A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B

This web-based database was launched on June 30, 2012 and consists of tertiary or secondary hospitals with special interest and expertise on managing hepatitis B patients across mainland China. The main inclusion criteria for this registration are HBsAg-positivity 6 months, HBeAg positive or negative, with or without cirrhosis, either treatment-nave ...

Phase N/A

0.0 miles

Learn More »

The Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)

The purpose of the study is to test whether the health care provider access and training in CERTAIN (Checklist for Early Recognition and Treatment of Acute Illness), would facilitate timely and error free best-practice delivery and minimize preventable death and costly complications in critically ill patients.

Phase N/A

0.0 miles

Learn More »